B. Riley Securities Reiterates Rating on ELTX $ELTX
Key Points
- B. Riley Securities now rates Elicio Therapeutics, Inc. ($ELTX) "buy" with a $27.00 target.
- The Street's average $ELTX price target is $20.67 (Strong Buy).
- $ELTX last traded around $14.85.
B. Riley Securities reiterated its rating on Elicio Therapeutics, Inc. ($ELTX) to a "buy" rating, with a price target of $27.00 in a recent research note.
Elicio Therapeutics, Inc. ($ELTX) Stock
Elicio Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.